(E)-5-methyl-4-oxohex-2-enoic acid | 35504-76-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: (E)-5-methyl-4-oxohex-2-enoic acid
• 英文别名: trans-3-Isobutyrylacrylsaeure；5-methyl-4-oxo-hex-2t-enoic acid；5-Methyl-4-oxo-hex-2t-ensaeure
• CAS: 35504-76-8
• 化学式: C₇H₁₀O₃
• 分子量: 142.155
• InChiKey: TZKNMZPMBZQSMV-ONEGZZNKSA-N

物化性质

• 熔点：
  81-83 °C
• 沸点：
  274.4±23.0 °C(Predicted)
• 密度：
  1.094±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (E)-5-methyl-4-oxohex-2-enoic acid 、 2,3-二甲基-1,3-丁二烯 在 四氯化钛 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 6-acetyl-3,4-dimethylcyclohex-3-enecarboxylic acid
  参考文献：
  名称：

  β-酰基丙烯酸的狄尔斯-阿尔德反应

  摘要：

  摘要 β-酰基丙烯酸与二烯的 Diels-Alder 反应在使用路易斯酸的情况下产生了良好的收率和相应环加成产物的良好区域或立体选择性。图形概要

  DOI：

  10.1080/00397911.2012.686002
• 作为产物：
  描述：

  ethyl 4-bromo-2,2-dimethyl-3-oxobutyrate 在 盐酸 、 碳酸氢钠 、 苯 作用下， 生成 (E)-5-methyl-4-oxohex-2-enoic acid
  参考文献：
  名称：

  Ellington et al., Journal of the Chemical Society, 1959, p. 80,84

  摘要：

  DOI：

文献信息

• Microwave-assisted synthesis of 4-oxo-2-butenoic acids by aldol-condensation of glyoxylic acid
  作者：Mélanie Uguen、Conghao Gai、Lukas J. Sprenger、Hang Liu、Andrew G. Leach、Michael J. Waring

  DOI：10.1039/d1ra05539a

  日期：——

  4-Oxobutenoic acids are useful as biologically active species and as versatile intermediates for further derivatisation. Currently, routes to their synthesis can be problematic and lack generality. Reaction conditions for the synthesis of 4-oxo-2-butenoic acid by microwave-assisted aldol-condensation between methyl ketone derivatives and glyoxylic acid have been developed. They provide the desired

  4-氧代丁烯酸可用作生物活性物质和用于进一步衍生化的通用中间体。目前，它们的合成路线可能存在问题并且缺乏通用性。开发了甲基酮衍生物与乙醛酸微波辅助羟醛缩合合成4-氧代-2-丁烯酸的反应条件。他们通过对可获得的起始材料应用简单的程序，以中等至优异的产率为各种底物提供所需的产品。研究表明，根据甲基酮取代基的性质，需要不同的条件，芳基衍生物使用对甲苯磺酸反应最好，而脂肪族底物与吡咯烷和乙酸反应最好。这种取代基效应通过前沿轨道计算得到合理化。总的来说，这项工作提供了在多种底物上合成 4-氧代丁烯酸的方法。
• Treatment of viral infections by modulation of host cell metabolic pathways
  申请人：Munger Josh

  公开号：US20090239830A1

  公开（公告）日：2009-09-24

  Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.

  描述了在病毒感染时发生的某些代谢物浓度和通量的改变。选择涉及代谢途径的宿主细胞酶作为干预靶点；即恢复代谢通量以不利于病毒复制，或进一步扰乱代谢通量导致病毒感染细胞的“自杀”（但不包括未感染的细胞），以限制病毒传播。虽然可以选择相关代谢途径中的任何酶，但是在这些代谢途径中关键控制点的关键酶更适合作为候选抗病毒药物靶点。使用这些酶的抑制剂来逆转或重定向病毒感染的影响。使用体外筛选分析和宿主细胞以及动物模型测试药物候选物的抗病毒活性。然后使用动物模型测试候选化合物在预防和治疗病毒感染方面的功效。证明了酶抑制剂的抗病毒活性。
• TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS
  申请人：MUNGER Josh

  公开号：US20130065850A1

  公开（公告）日：2013-03-14

  Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated.

  描述了某些代谢物浓度和通量的改变，这些改变是对病毒感染的反应。选择参与代谢途径的宿主细胞酶作为干预的目标，即恢复代谢通量以削弱病毒复制，或进一步扰乱代谢通量导致病毒感染细胞的“自杀”（但不包括未感染的细胞），以限制病毒传播。虽然可以选择相关代谢途径中的任何酶，但是在这些代谢途径的关键控制点上的关键酶被优先选择作为候选抗病毒药物靶点。使用这些酶的抑制剂来扭转或重定向病毒感染的影响。通过体外和宿主细胞的筛选试验以及动物模型来测试药物候选物的抗病毒活性。然后使用动物模型来测试候选化合物在预防和治疗病毒感染方面的功效。证明了酶抑制剂的抗病毒活性。
• SMALL MOLECULE BCL-X1/BCL-2 BINDING INHIBITORS
  申请人：Chen Ching-Shih

  公开号：US20100168184A1

  公开（公告）日：2010-07-01

  Bcl-xL/Bcl-2 binding inhibitors useful in the treatment of unwanted proliferating cells, including cancers and precancers, in subjects in need of such treatment. Also provided are methods of treating a subject having unwanted proliferating cells comprising administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject in need of such treatment. Also provided are methods of preventing the proliferation of unwanted proliferating cells, such as cancers and precancers, in a subject comprising the step of administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject at risk of developing a condition characterized by unwanted proliferating cells.
• Binding Inhibitors of the Beta. Transducin Repeat-Containing Protein
  申请人：Bradley Mark

  公开号：US20140315784A1

  公开（公告）日：2014-10-23

  The present invention relates to compounds which bind to Beta Trans-ducin repeat-containing protein (PTrCP), and modulate the activity of 13TrCP. In particular, the invention relates to compounds which demonstrate optimised binding to PTrCP. The invention also relates to pharmaceutical compositions comprising such compounds and the use of such compounds as medicaments, specifically for the treatment of disorders associated with aberrant protein degradation, such as cancer. The preferred binding inhibitors are peptides derived from the motive DSGXXS, e.g. DEGFWE, DDGFWD and Succinyl-EGFWE.